{"protocolSection": {"identificationModule": {"nctId": "NCT02924064", "orgStudyIdInfo": {"id": "MP-513-C03"}, "organization": {"fullName": "Mitsubishi Tanabe Pharma Corporation", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-09"}, "primaryCompletionDateStruct": {"date": "2018-09-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-09-26", "studyFirstSubmitQcDate": "2016-10-03", "studyFirstPostDateStruct": {"date": "2016-10-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-11-21", "resultsFirstSubmitQcDate": "2021-11-21", "resultsFirstPostDateStruct": {"date": "2022-01-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-02-24", "lastUpdatePostDateStruct": {"date": "2022-03-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Mitsubishi Tanabe Pharma Corporation", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 247, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Teneligliptin 20mg", "type": "EXPERIMENTAL", "description": "Teneligliptin (20mg once daily) for 24 weeks in combination with metformin", "interventionNames": ["Drug: Teneligliptin 20mg", "Drug: Metformin \u2265 1000 mg"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo for 24 weeks in combination with metformin", "interventionNames": ["Drug: Placebo", "Drug: Metformin \u2265 1000 mg"]}], "interventions": [{"type": "DRUG", "name": "Teneligliptin 20mg", "armGroupLabels": ["Teneligliptin 20mg"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin \u2265 1000 mg", "armGroupLabels": ["Placebo", "Teneligliptin 20mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Changes in HbA1c at Week 24", "description": "The change in HbA1c from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.", "timeFrame": "at Day 1(baseline) and Week 24"}], "secondaryOutcomes": [{"measure": "The Changes in Fasting Plasma Glucose (FPG) at Week 24", "description": "The change in FPG from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.", "timeFrame": "at Day 1(baseline) and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* A signed and dated informed consent form obtained from the subject, in accordance.\n* The subject is aged \u226518 years at signature of the informed consent form.\n* Hospitalization status: outpatient.\n* The subject has a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit (Day -28).\n* The subject's type 2 diabetes mellitus is managed by metformin monotherapy \u22651000 mg/day plus diet and exercise therapy, and the dosage or dose regimen of metformin and diet and exercise regimen has not been changed for at least 8 consecutive weeks at the screening visit (Day -28). Subjects who cannot do exercise due to complication are not limited to this criteria.\n* The subject's HbA1c is \u2265 7.0% and \\< 10.0% at the screening visit (Day -28) and on Day -14.\n\nExclusion Criteria:\n\n* The subject has a history of type 1 diabetes mellitus or a secondary form of diabetes.\n* The subject has received insulin within 1 year prior to the screening visit (Day -28), with the exception of insulin therapy during hospitalization or insulin therapy for medical conditions not requiring hospitalization (\\< 2 weeks' duration).\n* The subject has received an anti-diabetic drug within 8 weeks prior to the screening visit (Day -28).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "General Manager", "affiliation": "Mitsubishi Tanabe Pharma Corporation", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational center", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Teneligliptin 20mg + Metformin", "description": "Teneligliptin (20 mg once daily) for 24 weeks in combination with metformin."}, {"id": "FG001", "title": "Placebo + Metformin", "description": "Placebo for 24 weeks in combination with metformin."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "123"}, {"groupId": "FG001", "numSubjects": "124"}]}, {"type": "FAS", "achievements": [{"groupId": "FG000", "numSubjects": "122"}, {"groupId": "FG001", "numSubjects": "124"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "99"}, {"groupId": "FG001", "numSubjects": "81"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "43"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "29"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "FAS: All subjects in the randomized set who have received at least one dose of study medication during the double-blind treatment period and have at least one post-baseline efficacy observation. Subjects who were not diagnosed with type 2 diabetes mellitus were excluded.", "groups": [{"id": "BG000", "title": "Teneligliptin 20mg + Metformin", "description": "Teneligliptin (20 mg once daily) for 24 weeks in combination with metformin."}, {"id": "BG001", "title": "Placebo + Metformin", "description": "Placebo for 24 weeks in combination with metformin."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "122"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "246"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.0", "spread": "9.8"}, {"groupId": "BG001", "value": "54.7", "spread": "10.1"}, {"groupId": "BG002", "value": "55.3", "spread": "10.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "98"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "148"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "122"}, {"groupId": "BG001", "value": "124"}, {"groupId": "BG002", "value": "246"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Changes in HbA1c at Week 24", "description": "The change in HbA1c from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.", "populationDescription": "All subjects in the randomized set who have received at least one dose of study medication during the double-blind treatment period and have at least one post-baseline efficacy observation. Subjects who were not diagnosed with type 2 diabetes mellitus were excluded.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "at Day 1(baseline) and Week 24", "groups": [{"id": "OG000", "title": "Teneligliptin 20mg + Metformin", "description": "Teneligliptin (20 mg once daily) for 24 weeks in combination with metformin."}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo for 24 weeks in combination with metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.72", "spread": "0.07"}, {"groupId": "OG001", "value": "-0.01", "spread": "0.07"}]}]}]}, {"type": "SECONDARY", "title": "The Changes in Fasting Plasma Glucose (FPG) at Week 24", "description": "The change in FPG from baseline to Week 24 in Teneligliptin compared to Placebo was performed on FAS.", "populationDescription": "All subjects in the randomized set who have received at least one dose of study medication during the double-blind treatment period and have at least one post-baseline efficacy observation. Subjects who were not diagnosed with type 2 diabetes mellitus were excluded.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "at Day 1(baseline) and Week 24", "groups": [{"id": "OG000", "title": "Teneligliptin 20mg + Metformin", "description": "Teneligliptin (20 mg once daily) for 24 weeks in combination with metformin."}, {"id": "OG001", "title": "Placebo + Metformin", "description": "Placebo for 24 weeks in combination with metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.5", "spread": "3.3"}, {"groupId": "OG001", "value": "3.0", "spread": "3.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "24 weeks", "description": "All subjects in the randomized set who have received at least one dose of study medication during the double-blind treatment period. One subject who had been randomized in placebo group was handled as Teneligliptin group, because the subject had been administered Teneligliptin mistakenly.", "eventGroups": [{"id": "EG000", "title": "Teneligliptin 20mg + Metformin", "description": "Teneligliptin (20 mg once daily) for 24 weeks in combination with metformin.", "deathsNumAffected": 0, "deathsNumAtRisk": 124, "seriousNumAffected": 4, "seriousNumAtRisk": 124, "otherNumAffected": 35, "otherNumAtRisk": 124}, {"id": "EG001", "title": "Placebo + Metformin", "description": "Placebo for 24 weeks in combination with metformin.", "deathsNumAffected": 0, "deathsNumAtRisk": 123, "seriousNumAffected": 6, "seriousNumAtRisk": 123, "otherNumAffected": 43, "otherNumAtRisk": 123}], "seriousEvents": [{"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Gastric polyps", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Osteoarthropathy", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 123}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 123}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 123}]}, {"term": "Proteinuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 123}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 124}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 123}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Clinical Trials, Information Desk", "organization": "Mitsubishi Tanabe Pharma Corporation", "email": "cti-inq-ml@ml.mt-pharma.co.jp", "phone": "Please e-mail"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-04-29", "uploadDate": "2021-11-15T03:41", "filename": "Prot_000.pdf", "size": 2152228}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-12-11", "uploadDate": "2021-11-15T03:42", "filename": "SAP_001.pdf", "size": 1222460}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}